Quarterly ResultAug 5, 2026, 08:16 AM
ImageneBio Q2 Net Loss $(10.18)M; Cash $94.68M; $28M Private Placement
AI Summary
ImageneBio, Inc. reported a net loss of $10.18 million for the second quarter of 2026 and $20.80 million for the six months ended June 30, 2026. As of June 30, 2026, the company held $94.68 million in cash and cash equivalents. During the period, ImageneBio successfully completed a private placement, raising $28.05 million from the issuance of pre-funded warrants. The filing also provided context on the July 2025 merger of Ikena Oncology and Inmagene Biopharmaceuticals, which led to the formation of ImageneBio, Inc., and the subsequent divestiture of non-IMG-007 assets.
Key Highlights
- Net loss for the three months ended June 30, 2026, was $(10.18) million.
- Net loss for the six months ended June 30, 2026, was $(20.80) million.
- Cash and cash equivalents totaled $94.68 million as of June 30, 2026.
- Proceeds from the 2026 private placement were $28.05 million.
- Research and development expenses for six months ended June 30, 2026, were $12.63 million.
- General and administrative expenses for six months ended June 30, 2026, were $11.23 million.
- Total liabilities as of June 30, 2026, decreased to $9.97 million from $19.84 million.
- The company was formed from the merger of Ikena Oncology and Inmagene Biopharmaceuticals in July 2025.
Price Impact
More from IMA